The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH AL 2020 | VOD: treatment and prevention
Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the prevention and management of hepatic veno-occlusive disease (VOD) following hematopoietic stem cell transplantation (HSCT). Additionally, Dr Giralt outlines maintenance therapies, in particular after allogeneic HSCT. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
